Glucocorticoids are highly effective in treating inflammatory conditions. However, these medications also pose a significant risk for bone loss and fracture. In this slideshow, we cover the treatment guidelines.
Whitney J. Palmer
Active psoriatic arthritis and ankylosing spondylitis can lead to adverse pregnancy outcomes, which grows with corticosteroid use, a study shows.
Real-world applications of non-biologic treatments in children with juvenile idiopathic arthritis may be effective in controlling or maintaining the condition in some patients, new research shows.
To help clinicians manage antirheumatic drug therapy, the ACR and the American Association of Hip and Knee Surgeons developed evidence-based guidelines for the perioperative management of antirheumatic medication for patients with rheumatic diseases undergoing knee or hip surgery. In this slideshow, we outline those recommendations.
The JAK inhibitor tofacitinib presents a comparably low risk of venous thromboembolism to rheumatoid arthritis patients as do TNFi inhibitors, according to a new study.
Tofacitinib 5 mg or 10 mg twice daily with methotrexate can sustain improvements for 24 months, one study shows.
Baricitinib treatment does not increase the risk for cardiovascular problems in patients with rheumatoid arthritis, according to new research.
Rheumatoid arthritis patients taking tofacitinib could face some increased risks for significant cardiovascular events, depending upon their underlying characteristics, according to the results of a new study.
Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.
Identifying the type of depression present in an individual with or at-risk for symptomatic knee osteoarthritis can help clinicians best target therapies to reduce pain and disability over time, according to a new study.